These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32285369)

  • 1. Dynamic Culture Systems and 3D Interfaces Models for Cancer Drugs Testing.
    Fernandes DC; Canadas RF; Reis RL; Oliveira JM
    Adv Exp Med Biol; 2020; 1230():137-159. PubMed ID: 32285369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioreactors and Microfluidics for Osteochondral Interface Maturation.
    Canadas RF; Marques AP; Reis RL; Oliveira JM
    Adv Exp Med Biol; 2018; 1059():395-420. PubMed ID: 29736584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microengineered 3D Tumor Models for Anti-Cancer Drug Discovery in Female-Related Cancers.
    Amirghasemi F; Adjei-Sowah E; Pockaj BA; Nikkhah M
    Ann Biomed Eng; 2021 Aug; 49(8):1943-1972. PubMed ID: 33403451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbioreactors for high-throughput cytotoxicity assays.
    Yang ST; Zhang X; Wen Y
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):111-27. PubMed ID: 18175274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D Engineering of Ocular Tissues for Disease Modeling and Drug Testing.
    Boutin ME; Hampton C; Quinn R; Ferrer M; Song MJ
    Adv Exp Med Biol; 2019; 1186():171-193. PubMed ID: 31654390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D modeling in cancer studies.
    Atat OE; Farzaneh Z; Pourhamzeh M; Taki F; Abi-Habib R; Vosough M; El-Sibai M
    Hum Cell; 2022 Jan; 35(1):23-36. PubMed ID: 34761350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer drug discovery: recent innovative approaches to tumor modeling.
    Lovitt CJ; Shelper TB; Avery VM
    Expert Opin Drug Discov; 2016 Sep; 11(9):885-94. PubMed ID: 27454169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organotypic cancer tissue models for drug screening: 3D constructs, bioprinting and microfluidic chips.
    Radhakrishnan J; Varadaraj S; Dash SK; Sharma A; Verma RS
    Drug Discov Today; 2020 May; 25(5):879-890. PubMed ID: 32165322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mimicking Tumors: Toward More Predictive In Vitro Models for Peptide- and Protein-Conjugated Drugs.
    van den Brand D; Massuger LF; Brock R; Verdurmen WP
    Bioconjug Chem; 2017 Mar; 28(3):846-856. PubMed ID: 28122451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microfluidics Enabled Bottom-Up Engineering of 3D Vascularized Tumor for Drug Discovery.
    Agarwal P; Wang H; Sun M; Xu J; Zhao S; Liu Z; Gooch KJ; Zhao Y; Lu X; He X
    ACS Nano; 2017 Jul; 11(7):6691-6702. PubMed ID: 28614653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-dimensional in vitro tumor models for cancer research and drug evaluation.
    Xu X; Farach-Carson MC; Jia X
    Biotechnol Adv; 2014 Nov; 32(7):1256-1268. PubMed ID: 25116894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput screening with nanoimprinting 3D culture for efficient drug development by mimicking the tumor environment.
    Yoshii Y; Furukawa T; Waki A; Okuyama H; Inoue M; Itoh M; Zhang MR; Wakizaka H; Sogawa C; Kiyono Y; Yoshii H; Fujibayashi Y; Saga T
    Biomaterials; 2015 May; 51():278-289. PubMed ID: 25771018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring tumor response to anticancer drugs using stable three-dimensional culture in a recyclable microfluidic platform.
    Liu W; Xu J; Li T; Zhao L; Ma C; Shen S; Wang J
    Anal Chem; 2015 Oct; 87(19):9752-60. PubMed ID: 26337449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening.
    Heylman C; Sobrino A; Shirure VS; Hughes CC; George SC
    Exp Biol Med (Maywood); 2014 Sep; 239(9):1240-54. PubMed ID: 24740872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of mesenchymal stem cell 3D microenvironment: From macro to microfluidic bioreactors.
    Sart S; Agathos SN; Li Y; Ma T
    Biotechnol J; 2016 Jan; 11(1):43-57. PubMed ID: 26696441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiologically relevant in vitro tumor models for drug screening.
    Das V; Bruzzese F; Konečný P; Iannelli F; Budillon A; Hajdúch M
    Drug Discov Today; 2015 Jul; 20(7):848-55. PubMed ID: 25908576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D-3 Tumor Models in Drug Discovery for Analysis of Immune Cell Infiltration.
    Osswald A; Hedrich V; Sommergruber W
    Methods Mol Biol; 2019; 1953():151-162. PubMed ID: 30912021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Cancer Drug Validation: the Contribution of Tissue Engineered Models.
    Carvalho MR; Lima D; Reis RL; Oliveira JM; Correlo VM
    Stem Cell Rev Rep; 2017 Jun; 13(3):347-363. PubMed ID: 28233276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond 3D culture models of cancer.
    Tanner K; Gottesman MM
    Sci Transl Med; 2015 Apr; 7(283):283ps9. PubMed ID: 25877888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs.
    Santo VE; Rebelo SP; Estrada MF; Alves PM; Boghaert E; Brito C
    Biotechnol J; 2017 Jan; 12(1):. PubMed ID: 27966285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.